Longitudinal changes in procalcitonin in a heterogeneous group of critically ill patients

Critical Care Medicine

Volumn 40, Issue 10, 2012, Pages 2781-2787

  Reynolds, Steven C ^a,b   Shorr, Andrew F ^c   Muscedere, John ^d,e   Jiang, Xuran ^e   Heyland, Daren K ^d,e  

^a ROYAL COLUMBIAN HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d QUEEN S UNIVERSITY   (Canada)

^e KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

incident; infection; outcome; prevalent; procalcitonin; shock

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; DOPAMINE; NORADRENALIN; PHENYLEPHRINE; PROCALCITONIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; ELECTIVE SURGERY; FEMALE; GRAM STAINING; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFECTION; INTENSIVE CARE UNIT; LENGTH OF STAY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MICROORGANISM; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; SURGICAL WARD; TERTIARY HEALTH CARE;

AGED; CALCITONIN; CRITICAL ILLNESS; FEMALE; HUMANS; INFECTION; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SHOCK; TIME FACTORS;

EID: 84866553484     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31825b89cc     Document Type: Article

References (31)

1. Kumar A, Ellis P, Arabi Y, et al; Cooperative Antimicrobial Therapy of Septic Shock Database Research Group: Initiation of inappropriate antimicrobial therapy results in a fvefold reduction of survival in human septic shock. Chest 2009; 136:1237-1248
2. Micek ST, Ward S, Fraser VJ, et al: A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004; 125:1791-1799 (Pubitemid 38648413)
3. Lipman J, Boots R: A new paradigm for treating infections: "Go hard and go home". Crit Care Resusc 2009; 11:276-281
4. Eagye KJ, Kuti JL, Nicolau DP: Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomo-nas aeruginosa. Infect Control Hosp Epidemiol 2009; 30:746-752
5. Chastre J, Wolff M, Fagon JY, et al; PneumA Trial Group: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA 2003; 290:2588-2598 (Pubitemid 37443289)
6. Ibrahim EH, Ward S, Sherman G, et al: Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109-1115 (Pubitemid 32554320)
7. Dellinger R P, Levy MM, Carlet JM, et al; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
8. Pierrakos C, Vincent JL: Sepsis biomarkers: A review. Crit Care 2010; 14:R15
9. Briel M, Christ-Crain M, Young J, et al: Procal-citonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: Study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners [ISRCTN73182671]. BMC Fam Pract 2005; 6:34
10. Briel M, Schuetz P, Mueller B, et al: Procal-citonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008; 168:2000-2007; discussion 2007-2008
11. Christ-Crain M, Stolz D, Bingisser R, et al: Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial. Am J Respir Crit Care Med 2006; 174:84-93 (Pubitemid 43955248)
12. Müller F, Christ-Crain M, Bregenzer T, et al; ProHOSP Study Group: Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: A prospective cohort trial. Chest 2010; 138:121-129
13. Schuetz P, Christ-Crain M, Thomann R, et al; ProHOSP Study Group: Effect of procalcito-nin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: The ProHOSP randomized controlled trial. JAMA 2009; 302:1059-1066
14. Schuetz P, Christ-Crain M, Wolbers M, et al; ProHOSP Study Group: Procalcitonin guided antibiotic therapy and hospitaliza-tion in patients with lower respiratory tract infections: A prospective, multicenter, randomized controlled trial. BMC Health Serv Res 2007; 7:102
15. Stolz D, Christ-Crain M, Bingisser R, et al: Antibiotic treatment of exacerbations of COPD: A randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131:9-19 (Pubitemid 46122969)
16. Bouadma L, Luyt CE, Tubach F, et al; PRO-RATA Trial Group: Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): A mul-ticentre randomised controlled trial. Lancet 2010; 375:463-474
17. Hochreiter M, Köhler T, Schweiger AM, et al: Procalcitonin to guide duration of antibiotic therapy in intensive care patients: A randomized prospective controlled trial. Crit Care 2009; 13:R83
18. Nobre V, Harbarth S, Graf JD, et al: Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial. Am J Respir Crit Care Med 2008; 177:498-505 (Pubitemid 351442188)
19. Schroeder S, Hochreiter M, Koehler T, et al: Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: Results of a prospective randomized study. Langenbecks Arch Surg 2009; 394:221-226
20. Heyland DK, Johnson AP, Reynolds SC, et al: Procalcitonin for reduced antibiotic exposure in the critical care setting: A systematic review and an economic evaluation. Crit Care Med 2011; 39:1792-1799
21. Heyland DK, Govert J, Garrard C: Waveform abnormalities of APTT in critically ill hospitalized patients: The WATTCH study. Crit Care Med 2006; 34:A100
22. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classifcation system. Crit Care Med 1985; 13:818-829 (Pubitemid 15250137)
23. Moreno R, Vincent JL, Matos R, et al: The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med 1999; 25:686-696 (Pubitemid 29376122)
24. Garner JS, Jarvis WR, Emori TG, et al: CDC defnitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128-140
25. Rothman KJ: No adjustments are needed for multiple comparisons. Epidemiology 1990; 1:43-46 (Pubitemid 20255621)
26. Gilbert DN: Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 2010; 48:2325-2329
27. Schuetz P, Chiappa V, Briel M, et al: Procalci-tonin algorithms for antibiotic therapy decisions. Arch Intern Med 2011; 171:1322-1331
28. Giamarellos-Bourboulis EJ, Tsangaris I, Kanni T, et al; Hellenic Sepsis Study Group: Procalcitonin as an early indicator of outcome in sepsis: A prospective observational study. J Hosp Infect 2011; 77:58-63
29. Russell JA: Management of sepsis. N Engl J Med 2006; 355:1699-1713 (Pubitemid 44583960)
30. Zetola N, Francis JS, Nuermberger EL, et al: Community-acquired meticillin-resis-tant Staphylococcus aureus: An emerging threat. Lancet Infect Dis 2005; 5:275-286 (Pubitemid 40602247)
31. Hochreiter M, Köhler T, Schweiger AM, et al: [Antibiotic treatment of surgical intensive care patients: Procalcitonin to guide duration of therapy]. Anaesthesist 2008; 57:571-577